NI201200085A - Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina - Google Patents
Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopinaInfo
- Publication number
- NI201200085A NI201200085A NI201200085A NI201200085A NI201200085A NI 201200085 A NI201200085 A NI 201200085A NI 201200085 A NI201200085 A NI 201200085A NI 201200085 A NI201200085 A NI 201200085A NI 201200085 A NI201200085 A NI 201200085A
- Authority
- NI
- Nicaragua
- Prior art keywords
- strescopin
- heart failure
- subject
- treat heart
- type peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 abstract 1
- 101800000414 Corticotropin Proteins 0.000 abstract 1
- 102000016983 Releasing hormones receptors Human genes 0.000 abstract 1
- 108070000025 Releasing hormones receptors Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 abstract 1
- 229960000258 corticotropin Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a nuevos métodos de tratamiento de la insuficiencia cardiaca que comprende administrar una cantidad de péptido tipo estrescopina a un sujeto que lo necesita; y mantener sustancialmente la cantidad de dicho péptido presente en el plasma de dicho sujeto en una concentración que resulta en un beneficio terapéutico sin un incremento sustancial en el ritmo cardíaco de dicho sujeto. El método implica el uso de péptidos tipo estrescopina que son antagonistas selectivos del receptor de hormonas de liberación de corticotrofina de tipo 2 (CRHR2).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25818109P | 2009-11-04 | 2009-11-04 | |
| US12/612,548 US10040838B2 (en) | 2008-11-04 | 2009-11-04 | CRHR2 peptide agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201200085A true NI201200085A (es) | 2012-08-17 |
Family
ID=43926060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201200085A NI201200085A (es) | 2009-11-04 | 2012-05-04 | Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110105397A1 (es) |
| EP (1) | EP2496248A2 (es) |
| JP (1) | JP2013510167A (es) |
| KR (1) | KR20120103606A (es) |
| CN (1) | CN102711801A (es) |
| AU (1) | AU2010315131A1 (es) |
| BR (1) | BR112012010661A2 (es) |
| CA (1) | CA2780163A1 (es) |
| CO (1) | CO6541617A2 (es) |
| EA (1) | EA201290278A1 (es) |
| IL (1) | IL219565A0 (es) |
| MX (1) | MX2012005262A (es) |
| NI (1) | NI201200085A (es) |
| WO (1) | WO2011057027A2 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010053990A2 (en) * | 2008-11-04 | 2010-05-14 | Janssen Pharmaceutica Nv | Crhr2 peptide agonists and uses thereof |
| EP2814513B1 (en) | 2012-02-14 | 2017-12-20 | The Regents of The University of California | Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions |
| US20160166651A1 (en) * | 2014-04-03 | 2016-06-16 | The Regents Of The University Of California | Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunctions and congestive heart failure |
| US20160161489A1 (en) * | 2014-09-15 | 2016-06-09 | Mark W. Linder | Urine-based immuncassay for urocirtub 3 abd duagbisus if skeeo aobea |
| JOP20170153A1 (ar) | 2016-07-15 | 2019-01-30 | Lilly Co Eli | نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة |
| AU2017345785A1 (en) * | 2016-10-20 | 2019-05-16 | Cortene Inc. | Methods of treating diseases resulting from a maladapted stress response |
| WO2018090042A1 (en) * | 2016-11-14 | 2018-05-17 | Renova Therapeutics, Inc. | Methods of treating heart failure |
| WO2018090036A1 (en) * | 2016-11-14 | 2018-05-17 | Renova Therapeutics, Inc. | Method of protection for cardiac tissue |
| EP4308150A1 (en) * | 2021-03-17 | 2024-01-24 | Cortene Inc. | Improved methods of treating diseases resulting from a maladapted stress response |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2127458T3 (es) | 1989-11-06 | 1999-04-16 | Cell Genesys Inc | Produccion de proteinas utilizando recombinacion homologa. |
| US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
| EP0922446A1 (en) * | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Solution-phase site-specific preparation of GRF-PEG conjugates |
| US6420339B1 (en) * | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| US20020082409A1 (en) * | 2000-10-26 | 2002-06-27 | Hsu Sheau Yu | Stresscopins and their uses |
| US6673580B2 (en) | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
| NZ524477A (en) * | 2001-03-15 | 2004-11-26 | Res Dev Foundation | Urocortin-III and uses thereof |
| ATE333290T1 (de) | 2001-05-21 | 2006-08-15 | Injet Digital Aerosols Ltd | Zusammensetzungen für die freisetzung von protein auf dem pulmonalen weg |
| US6936585B2 (en) * | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
| KR100512483B1 (ko) * | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
| GB0316294D0 (en) * | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| EP1675620B1 (en) * | 2003-10-09 | 2019-05-08 | Ambrx, Inc. | Polymer derivatives |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| EP2114437A2 (en) | 2006-10-16 | 2009-11-11 | ConjuChem Biotechnologies Inc. | Modified corticotropin releasing factor peptides and uses thereof |
| US20100249027A1 (en) * | 2007-05-25 | 2010-09-30 | William Henry | Crf conjugates with extended half-lives |
| WO2010053990A2 (en) * | 2008-11-04 | 2010-05-14 | Janssen Pharmaceutica Nv | Crhr2 peptide agonists and uses thereof |
-
2010
- 2010-11-04 AU AU2010315131A patent/AU2010315131A1/en not_active Abandoned
- 2010-11-04 CN CN2010800606204A patent/CN102711801A/zh active Pending
- 2010-11-04 BR BR112012010661A patent/BR112012010661A2/pt not_active IP Right Cessation
- 2010-11-04 WO PCT/US2010/055526 patent/WO2011057027A2/en active Application Filing
- 2010-11-04 JP JP2012538004A patent/JP2013510167A/ja not_active Withdrawn
- 2010-11-04 CA CA2780163A patent/CA2780163A1/en not_active Abandoned
- 2010-11-04 EP EP10779603A patent/EP2496248A2/en not_active Withdrawn
- 2010-11-04 KR KR1020127014226A patent/KR20120103606A/ko not_active Application Discontinuation
- 2010-11-04 US US12/940,019 patent/US20110105397A1/en not_active Abandoned
- 2010-11-04 MX MX2012005262A patent/MX2012005262A/es not_active Application Discontinuation
- 2010-11-04 EA EA201290278A patent/EA201290278A1/ru unknown
-
2012
- 2012-05-03 IL IL219565A patent/IL219565A0/en unknown
- 2012-05-04 NI NI201200085A patent/NI201200085A/es unknown
- 2012-05-30 CO CO12090200A patent/CO6541617A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL219565A0 (en) | 2012-06-28 |
| MX2012005262A (es) | 2012-09-28 |
| KR20120103606A (ko) | 2012-09-19 |
| US20110105397A1 (en) | 2011-05-05 |
| CN102711801A (zh) | 2012-10-03 |
| AU2010315131A1 (en) | 2012-05-31 |
| CO6541617A2 (es) | 2012-10-16 |
| WO2011057027A2 (en) | 2011-05-12 |
| EA201290278A1 (ru) | 2012-11-30 |
| WO2011057027A3 (en) | 2011-07-07 |
| BR112012010661A2 (pt) | 2016-11-22 |
| CA2780163A1 (en) | 2011-05-12 |
| EP2496248A2 (en) | 2012-09-12 |
| JP2013510167A (ja) | 2013-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201200085A (es) | Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina | |
| PE20190205A1 (es) | Uso de inhibidores de miostatina y terapias de combinacion | |
| CL2011001578A1 (es) | Anticuerpo que inhibe selectivamente al receptor del peptido relacionado al gen de la calcitonina ( cgrp r) humano; polinucleotido que lo codifica; vector; celula; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar un medicamento para tratar una condicion asociada con cgrp r en un paciente, como migraña. | |
| BR112018002046A2 (pt) | métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina | |
| PE20170140A1 (es) | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer | |
| BR112013003823A2 (pt) | conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados | |
| EA201291234A1 (ru) | Аналоги глюкагона | |
| ES2675779T3 (es) | Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| ECSP12011962A (es) | Tratamientos para trastornos gastrointestinales | |
| GT201700224A (es) | Proteína de unión a rgma y su uso | |
| AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
| MA32389B1 (fr) | Methode de traitement de la dyspnee associee a une insuffisance cardiaque aigue | |
| CU24043B1 (es) | Hormona foliculoestimulante humana recombinante, composición farmacéutica que la comprende | |
| EA201500802A1 (ru) | Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы | |
| NI201800086A (es) | Métodos para tratar la depresión con antagonistas del recptor de orexina-2 | |
| NI201200134A (es) | Polipéptidos agonistas que se enlazan a dr5 | |
| AR083395A1 (es) | Derivado peptidico nmu (neuromedina u) con elevado efecto anorectico | |
| MX2015012547A (es) | Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2. | |
| AR095611A1 (es) | Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1) | |
| CO6771410A2 (es) | Tratamiento terapeutico para el sindrome metabolico, diabetes tipo 2, obesidad o prediabetes | |
| CO6341479A2 (es) | Péptidos agonistas de crhr2 y usos de estos | |
| EA201690732A1 (ru) | Агонисты гуанилатциклазы, используемые для лечения индуцированных опиоидами дисфункций | |
| PE20160847A1 (es) | Nuevo compuesto para el tratamiento de hipoglicemia severa | |
| BR112018006572A2 (pt) | terapia de combinação racional para o tratamento de câncer |